Nasdaq apls
Fintel reports that on May 8, 2023, Citigroup maintained coverage of Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy recommendation.. Analyst Price Forecast Suggests 4.25% Downside. As of April ...Dec 1, 2023 · The average twelve-month price prediction for Apellis Pharmaceuticals is $66.50 with a high price target of $93.00 and a low price target of $29.00. Learn more on APLS's analyst rating history. Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors?
Did you know?
Analyst Price Forecast Suggests 203.86% Upside. As of July 6, 2023, the average one-year price target for Apellis Pharmaceuticals is 104.04. The forecasts range from a low of 76.76 to a high of ...Apellis Pharmaceuticals Inc (Symbol: APLS) saw options trading volume of 11,658 contracts, representing approximately 1.2 million underlying shares or approximately 61.6% of APLS's average daily ...WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Find the latest Earnings Report Date for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.
Funds + ETFs. After-Hours Quotes. See All Market Activity->. News + Insights.WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced ...Headline. APLS Jan 2025 120.000 put. finance.yahoo.com - November 23 at 9:19 AM. Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.7% After Insider Selling. americanbankingnews.com - November 23 at 1:49 AM. Alec Machiels Sells 1,250 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock. americanbankingnews.com - November 22 at 4:44 AM. The new research reports from Market Source Research, available for free download at the links above, examine Fibrocell Science Inc (NASDAQ:FCSC), Sears Hometown and Outlet Stores, Inc. (NASDAQ ...On October 12, 2023, Brian Cheng, an analyst at BofA Securities, expressed his viewpoint on Apellis Pharmaceuticals (NASDAQ:APLS). Despite maintaining a Neutral rating, Cheng increased the price target for the company from $44 to $46. It is worth noting that Apellis Pharmaceuticals has garnered a Strong Buy consensus among analysts, who have set a …
The public float for APLS is 97.67M, and at present, short sellers hold a 19.04% of that float. On November 06, 2023, the average trading volume of APLS was 3.32M shares. APLS) stock’s latest price update. The stock price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) has dropped by -3.80 compared to previous close of 46.83.Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower amid safety concerns regarding the company's newly launched Syfovre (pegcetacoplan injection) for geographic atrophy (GA ...May 4, 2023 · Operating as a commercial-stage biopharmaceutical entity, Apellis Pharmaceuticals (NASDAQ:APLS) is dedicated to the discovery, development, and market introduction of groundbreaking therapeutic ... ….
Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Nasdaq apls. Possible cause: Not clear nasdaq apls.
May 18, 2023 · deliormanli. Background. Apellis Pharmaceuticals (NASDAQ:APLS), is a US-based commercial biotech focused on innovative biologics that inhibit the complement system via C3 targeting.The firm's ... Find the latest Earnings Report Date for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.The average twelve-month price prediction for Apellis Pharmaceuticals is $66.50 with a high price target of $93.00 and a low price target of $29.00. Learn more on APLS's analyst rating history. Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors?
Funds + ETFs. After-Hours Quotes. See All Market Activity->. News + Insights.Find the latest Earnings Report Date for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.
topstock 2 Apellis Pharmaceuticals Inc (NASDAQ: APLS) stock’s 52-week price range is $33 – $94. The share price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) has plunged by a huge 60% in the past month, adding to the woes of its shareholders over the last year. Moreover, the stock has not done well, decreasing by 33.33% in the last six months. safe stock to buybuy gold cheapest Nov 29, 2023 · That number of contracts represents approximately 5.6 million underlying shares, working out to a sizeable 101.3% of VRT's average daily trading volume over the past month, of 5.5 million shares ... mandt bank home loan rates WALTHAM, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on ...Apellis Pharmaceuticals (NASDAQ:APLS) dropped 8.6% amid a new short call from Citron Research. Citron claims it wouldn't be surprised if the Food and Drug Administration "steps in with a warning ... westinghouse nuclear stockfx options trading platformforex candlestick patterns cheat sheet Funds + ETFs. After-Hours Quotes. See All Market Activity->. News + Insights. can you trade futures on robinhood Is Apellis Pharmaceuticals (NASDAQ:APLS) a buy? Compare the latest price, visualised quantitative ratios, annual reports, historical dividends, ...Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week May 13. Consensus revenue estimates increase by 57%, … warren buffett real estateotc brokeragenasdaq aep WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today provided an update on its New ...